In the context of pancreatic tumors treated with IRE, the IFNγ–JAK–STAT1–ISG pathway, immune functions of ISGs, and feedback inhibition of this pathway pose some key questions to be answered. This evidence concerns the gene IFNG and pancreatic neoplasm.